This is a preclinical update that validates the scientific rationale for an already-planned Phase IIb study — it does not change the binary risk profile of a pre-revenue biotech. The ESMO 2026 presentation of Phase IIa pancreatic data is the next meaningful catalyst. Monitor for enrollment updates on the Phase IIb trial and cash runway disclosures in the next 20-F or equity offering filings.
Price Chart
Executive Summary
Can-Fite BioPharma announced new preclinical findings showing namodenoson enhances gemcitabine's anti-cancer effect in pancreatic cancer by increasing apoptosis (cleaved caspase-3). The data provide mechanistic support for a planned Phase IIb study combining namodenoson with gemcitabine and Nab-paclitaxel, building on positive Phase IIa monotherapy results. This is a preclinical update with no new clinical data, financial figures, or regulatory milestones — it supports the scientific rationale for an already-planned trial but does not change the company's near-term risk profile or cash runway.
Key Facts
- Namodenoson combined with gemcitabine increased cleaved caspase-3 (apoptosis mediator) in preclinical pancreatic cancer models.
- Findings support the design of a planned randomized Phase IIb study in advanced pancreatic adenocarcinoma combining namodenoson with gemcitabine and Nab-paclitaxel.
- Phase IIa monotherapy results in pancreatic cancer have been accepted for presentation at ESMO Congress 2026.
- Namodenoson is also in a Phase III trial for HCC, a Phase IIb trial for MASH, and has Orphan Drug/Fast Track designations for HCC.
- No new financial data, cash runway updates, or regulatory milestones were disclosed.
Financial Impact
No financial figures disclosed. Preclinical data with no near-term revenue impact.
Risk Factors
- Preclinical findings may not translate to clinical efficacy in the planned Phase IIb study.
- Can-Fite has a history of losses and needs additional capital to fund operations — no cash runway update was provided.
- Pancreatic cancer is a notoriously difficult indication with high clinical trial failure rates.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-090478 |
| Document: ea0302324-6k_canfite.htm | 0001213900-26-090478 |
| Document: 0001213900-26-090478-index-headers.html | 0001213900-26-090478 |
| Document: 0001213900-26-090478-index.html | 0001213900-26-090478 |
| Document: 0001213900-26-090478.txt | 0001213900-26-090478 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.95 | awaiting T+5 | — | $1.65 (−15.13%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.65 (+15.13%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.65 (+15.13%) |
Sep 14, 2026 6w ago | EFFECT | $2.30 $2.22 | ▲ +3.48% | ▲ +3.58% | $1.65 (+28.04%) |
Sep 9, 2026 6w ago | 6-K | $2.19 $2.24 | ▲ +2.28% | ▲ +3.38% | $1.65 (−24.43%) |
Sep 3, 2026 7w ago | 6-K | $2.35 $2.33 | ▼ −0.85% | ▲ +0.30% | $1.65 (−29.57%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.65 (−29.87%) |
Sep 2, 2026 7w ago | Press Release | $2.36 $2.16 | ▲ +8.47% | ▲ +7.52% | $1.65 (+29.87%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.65 (−29.87%) |
Aug 17, 2026 10w ago | 6-K | $3.58 $3.35 | ▼ −6.42% | ▼ −5.23% | $1.65 (−53.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers